Milestone
2008
- Planning to start a Pharmaceutical Unit.
2009
- February- Formation Of Partnership Organization
- March- 1st Product Submission In TRINIDAD
- October- ISO 9001: 2008 Certified
2010
- June - 1st Product Registration in JAMAICA
- June- MOH Supply TO Trinidad & Tobago
- October- Launch of Domestics Business
2011
- February - MOH supply to JAMAICA
- April- MOH supply to CUBA
- May- MOH supply to EL SALVADOR
- October- Subsidiary Office in US
- August – Formation of Private Limited
2012
- March - 1st Product Registration in PANAMA
- April - MOH supply to PANAMA
- November- 1st Product Registration in Trinidad & Tobago
- Development of New Product – Hydralazine Hydrochloride Injection USP
- Development of New Product – Capecitabine Tablets USP
- Development of New Product –Bleomycin Injection USP
- Development of New Product –Doxorubicin Hydrochloride Injection USP
2013
- Jan- 1st Product Registration in HONDURAS
- July- MOH supply to JORDAN
- September-1st Product Registration in Dominican republic
- October- 1st Product Registration in EL SALVADOR
- December- 1st Product Registration in CUBA
- Development of New Product –Teicoplanin Injection
- Development of New Product –Tigecycline Injection
- Development of New Product –Premetrexed Injection
2014
- Development of New Product – Alprostadil Injection USP
- Development of New Product – Labetalol Hydrochloride Injection USP
- Development of New Product – Milrinone Lactate Injection
- Development of New Product – Caffeine Citrate Injection
2015
- Tech Transfer-Loratadine Oral solution USP 5mg/5ml
- 3 products submitted in specialty injectable and oncology segment
2016
- Tech Transfer –Bisoprolol Tablet in all strength
- Won tender for Antipsychotic range in Srilanka
- Received 9 registration in Srilanka
- 1st Product Registered in Cambodia
- Received 1St Registration in Namibia
- Introduced 30 plus New Formulation (products) for various markets across the Globe
- Room temperature Stable Leucovorin Injection Introduced in Papua New Guinea Market
- Purchase our own Manufacturing Plant which are specialized in Niche Liquid Injectable, Ophthalmic Range, and Derma Range.
- Registration of high end oncology products
- Initiated with private market in Jamaica & Dominican Republic
- CE Marked products supplied in Regulated market
- Supplied Biotechnology products in regulated market like Germany
- 2 products registered in large volume Parental segment IV fluid in Antibiotic and Antifungal Therapy for Turkmenistan
2017
- 1st Product registration in Botswana
- 1st Product registration in Mongolia
- 1st Product registration in Myanmar
- Enter in Bosnia (EU) Market
- Successfully Entered into Peru Market
- Won Tender in Burundi, Guyana, Libya & Iraq Market
2018
- Plant ISO 10002:2014 certified
- 1st registration received in Ecuador
- 1st oncology product registered in Nigeria
- 1st antipsychotic product registered in Cuba
- Received 44 registrations in Honduras & 12 registrations in Myanmar
- Received overall 105 product registrations & 76 product submissions in various countries
2019
- Received 1st approval of one Novel product from CDSCO, India
- 1st registration received in Uzbekistan, Laos, Georgia, Curacao
- Enter in Madagascar Market-1st product submitted
- Received 24 registrations in Honduras , 11 registrations in Myanmar, 5 oncology products in Nigeria
- Received overall 80 product registrations & 59 product submissions in various countries
- 1st Technology transfer -Algeria
- New product developed:
- Latanoprost eye drops
- Latanoprost + Timolol eye drops
- Ciprofloxacin +Dexamethasone Eye drops
- Ivermectin Cream & Lotion
- Hydroquinone cream 4%w/w
- Octreotide Acetate Injection 0.1mg & 0.05mg
- Trypan blue 0.06% ophthalmic solution
- Dexamethasone phosphate and neomycin eye/ear drops
- Carbomer eye gel 0.2%
- Naphazolin +Zinc sulphate eye drops (100 mcg +0.2 mg)
- Levocarnitin injection 200mg/ml
- Glycopyrolate Injection 0.2 mg/ml
- Glycopyrolate + Neostigmine Injection
- Dexpanthenol 5% ointment
- Naphazoline 0.025 % w/w+ Phenylephrine HCl 0.25% w/v Nasal drops
- HPMC eye gel 0.3%
- Tranexamic acid injection
- Nepafenac eye suspension
2020
- Company approval received from Bahamas
- Plant Inspected by Ministry of Yemen
- Received overall 45 product registrations & 66 product submissions in various countries
- Set up of new FND facility
- New product developed:
- Citicoline injection
- Nalbuphine injection
- Travoprost Eye drop
- Travoprost + timolol eye drops
- Phenytoin injection
- Ergocalciferol injection
- Neomycin+ Polymyxin + Bacitacin ointment
- Dimethicon lotion 4%
- Granisetron Hydrochloride Injection
- Bupivacaine and Adrenaline (Epinephrine) Injection
- Metamizole 100mg/ml injection
- Pancuronium bromide injection 2mg/ml
- Flumazenil injection 0.5mg/ml
- Cisatracurium Injection 2mg/ml
- Buprenorphin injection 0.3%
- Enoxaparin injection 100mg/ml, 3ml
- Naphazolin nasal drops 0.5%
- Acyclovir injection 25mg/ml
- Zinc gluconate injection1mg/ml
2021
- Crossed INR 1 BN
- 1st Overseas Acquisition
- Entry In API Business Market
- Received approval of Methylene Blue Injection 0.1% w/v (Blue Beam) from CDSCO, India.
- Plant renewed by NMRA (Sri Lanka)
- Plant equipped with new PFS facility
- 1st Narcotic analgesic product (Fentanyl injection) registered in Peru & Bolivia
- 1st registration of Veterinary product in Azerbaijan
- Enter in Kenya market: received 2 products registration
- 1st approval of Nutraceuticals in Myanmar (5 products)
- Submission of Biological products in Latam
- Site registration submitted for Philippines & Nepal
- Enter in new markets like Brazil, Niger, Cameroon, Ivory coast, Chad, Gabon, Benin, Mali, Senegal, Burkina Faso, Gambia, Saudi Arabia, Venezuela, Armenia, Aruba, etc
- New product developed:
- Trace elements injection USP
- Aminocaproic acid injection
- Ivermectin +Closantel injection
- Bepotastine eye drops 1.5%w/v
- Levobunolol eye drops BP 0.5%
- Desmopressin injection 4mcg
- KY Jelly
- Lignocaine Jelly
- Palonosetron Injection
- Zinc stearate ointment
- Azithromycin eye drops
- Vitamin AD3E & B-complex Injection
Copyright © Flagship : Corporate Business Services | Disclaimer | 